The KRAS oncogene is mutated in approximately 35%-45% of colorectal cancers, and
KRAS mutational status testing has been highlighted in recent years. The most frequent …

Prognosis of solid cancers is generally more favorable if the disease is treated early and
efficiently. A key to long cancer survival is in radical surgical therapy directed at the primary …

Point mutations in the Kirsten rat sarcoma viral oncogene homologue (KRAS) gene are
being increasingly recognized as important diagnostic and prognostic markers in cancer. In …

The detection of cancer biomarkers freely circulating in blood offers new opportunities for
cancer early diagnosis, patient follow-up, and therapy efficacy assessment based on liquid …

The utilization of archived, formalin-fixed paraffin-embedded (FFPE) tumor samples for
massive parallel sequencing has been challenging due to DNA damage and contamination …

Current genomic studies are limited by the availability of fresh tissue samples. Here, we
show that Illumina RNA sequencing of formalin-fixed diagnostic tumor samples produces …

BACKGROUND: KRAS status is a useful predictive marker for anti-epidermal growth factor
receptor antibody therapy. OBJECTIVE: This study aimed to examine the concordance rate …

Current genomic studies are limited by the poor availability of fresh-frozen tissue samples.
Although formalin-fixed diagnostic samples are in abundance, they are seldom used in …

KRAS mutation has been unambiguously identified as a marker of resistance to cetuximab-
based treatment in metastatic colorectal cancer (mCRC) patients. However, most studies of …

Activating point mutations in codons 12, 13, and 61 of the KRAS proto-oncogene are
common in colorectal, non–small cell lung, pancreatic, and thyroid cancers. Constitutively …